Education
About Us
Working with TipRanks
Follow Us
Sernova (TSE:SVA)
TSX:SVA
SVA Stock Chart & Stats
C$0.15
C$0.00(0.00%)
At close: 4:00 PM EST
C$0.15
C$0.00(0.00%)
Day’s Range― - ―
52-Week RangeC$0.12 - C$0.23
Previous CloseN/A
Volume71.45K
Average Volume (3M)125.66K
Market Cap
C$57.24M
Enterprise ValueC$74.26M
Total Cash (Recent Filing)C$265.00K
Total Debt (Recent Filing)C$17.28M
Price to Earnings (P/E)―
Beta-0.52
Next Earnings
Jun 12, 2026Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.01
Shares Outstanding336,698,550
10 Day Avg. Volume126,270
30 Day Avg. Volume125,661
Financial Highlights & Ratios
PEG Ratio0.06
Price to Book (P/B)-1.96
Price to Sales (P/S)0.00
P/FCF Ratio-4.51
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.02
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Proprietary Cell Pouch PlatformSernova’s Cell Pouch System is a platform-level, implantable device designed to host therapeutic cells, creating a durable competitive advantage. A platform can support multiple cell types and indications, raising long-term upside if clinical proof-of-concept is achieved and raising barriers to entry for competitors.
Improving Cash Burn TrajectoryMaterial reduction in operating cash outflow over successive years signals stronger cost discipline and more efficient development spending. Sustained lower burn can extend runway, reduce frequency of dilutive raises, and allow management to prioritize clinical milestones that drive durable value creation.
Debt-to-equity Conversion And FinancingsThe debt-to-equity conversion and recent financings materially reduce near-term interest and repayment pressure, improving balance-sheet breathing room. This structural recapitalization lowers immediate liquidity risk and supports continued clinical programs without imminent refinancing urgency.
Bears Say
Pre-revenue, No Commercial SalesNo commercial revenue means Sernova remains fully dependent on development success and external funding to reach commercialization. Absent revenue, durable profitability hinges on successful trials, regulatory approval, and scaling manufacturing—each a multi-year execution risk with potential dilution.
Negative Equity And Rising DebtWorsening equity and a sharp debt increase materially elevate refinancing and solvency risk. Negative equity constrains access to non-dilutive capital and may force financing on unfavorable terms, reducing strategic flexibility and increasing the chance that future capital raises dilute existing shareholders.
Free Cash Flow Negative; Funding DependencePersistently negative free cash flow indicates operations do not self-fund and the company will need additional capital to complete development. Reliance on external financing can delay projects, shift focus to fundraising, and increase dilution risk, all of which can hamper long-term value realization.
Sernova News
SVA FAQ
What was Sernova’s price range in the past 12 months?
Sernova lowest stock price was C$0.12 and its highest was C$0.23 in the past 12 months.
What is Sernova’s market cap?
Sernova’s market cap is C$57.24M.
When is Sernova’s upcoming earnings report date?
Sernova’s upcoming earnings report date is Jun 12, 2026 which is in 88 days.
How were Sernova’s earnings last quarter?
Sernova released its earnings results on Mar 13, 2026. The company reported -C$0.01 earnings per share for the quarter, the consensus estimate of -C$0.01 by C$0.
Is Sernova overvalued?
According to Wall Street analysts Sernova’s price is currently Overvalued.
Does Sernova pay dividends?
Sernova does not currently pay dividends.
What is Sernova’s EPS estimate?
Sernova’s EPS estimate is 0.
How many shares outstanding does Sernova have?
Sernova has 336,698,550 shares outstanding.
What happened to Sernova’s price movement after its last earnings report?
Sernova reported an EPS of -C$0.01 in its last earnings report, expectations of -C$0.01. Following the earnings report the stock price went same N/A.
Which hedge fund is a major shareholder of Sernova?
Currently, no hedge funds are holding shares in TSE:SVA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Sernova
Sernova Corp. operates as a clinical-stage regenerative medicine therapeutics company in Canada. The company focuses on the development and commercialization of regenerative medicine therapeutics, including its proprietary Cell Pouch and associated technologies consisting of therapeutic cells and local cellular immune protection. Its Cell Pouch is a medical device designed to create a vascularized tissue environment for the transplantation and engraftment of therapeutic cells, which then release proteins and/or hormones for the long-term treatment of various serious chronic diseases, such as diabetes, hemophilia, and thyroid disease. Sernova Corp. has a research collaboration with AgeX Therapeutics, Inc. to generate immune-protected therapeutic cells; and a research agreement with the University of Miami to advance the development of Cell Pouch cell therapy platform. The company was incorporated in 1998 and is headquartered in London, Canada.
Technical Analysis
Covalon Technologies
―
Microbix Biosystms
―
Medmira
―
NurExone Biologic
―
Defence Therapeutics
―